Not independent
Tenure on this board
1.6 yrs
Meeting calendar
AVR · Special meeting · Thursday, September 4, 2025
Anteris Technologies Global Corp
7 nominees · 2 ballot items.
Proposal 1: ASX Waiver Proposal; Proposal 2: Adjournment Proposal.
Market cap
$968M
1Y TSR
+116.1%
Board grade
B
Record date
Aug 11, 2025
Filing
DEF 14A
Meeting concluded · Sep 4, 2025
Follow how the vote landed and what changed on Anteris Technologies Global Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
THE ASX WAIVER PROPOSAL
ManagementBoard: FORApproval by stockholders of a waiver from ASX Listing Rule 7.1 to permit the Company to issue new securities without stockholder approval, for a three-year period and on the terms summarized in the Proxy Statement.
- 2
THE ADJOURNMENT PROPOSAL
ManagementBoard: FORApproval to adjourn the Special Meeting to solicit additional proxies if there are not sufficient votes to approve the ASX Waiver Proposal.
Director elections
Nominees on the ballot7
Not independent
Tenure on this board
1.6 yrs
Not independent
Tenure on this board
0.1 yrs
Independent
Tenure on this board
1.1 yrs
Independent
Tenure on this board
1.1 yrs
Also a director at
Lemaitre Vascular Inc (LMAT)
Not independent
Tenure on this board
1.3 yrs
Not independent
Tenure on this board
New nominee
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | L1 Capital Pty Ltd | 8.0% | 7,789,000 | $43M |
| 2 | Nantahala Capital Management, LLC | 5.7% | 5,530,910 | $31M |
| 3 | Sio Capital Management, LLC | 5.5% | 5,382,965 | $30M |
| 4 | ADAR1 Capital Management, LLC | 3.9% | 3,789,132 | $21M |
| 5 | PERCEPTIVE ADVISORS LLC | 3.5% | 3,425,476 | $19M |
| 6 | BVF INC/IL | 3.1% | 3,000,000 | $17M |
| 7 | RA CAPITAL MANAGEMENT, L.P. | 3.1% | 3,000,000 | $17M |
| 8 | BlackRock, Inc. | 2.8% | 2,705,371 | $15M |
| 9 | Ensign Peak Advisors, Inc | 2.1% | 2,087,111 | $12M |
| 10 | BlackRock, Inc. | 1.9% | 1,832,482 | $10M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Anteris Technologies Global Corp’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Esperion Therapeutics IncESPR
Special meeting·Jul 8, 2026·$814M
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Achieve Life Sciences IncACHV
Annual meeting·Jul 2, 2026·$670M
Xoma Royalty CorpXOMA
Annual meeting·Jul 13, 2026·$533M
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Reference
Frequently asked questions
- When is the Anteris Technologies Global Corp 2025 special meeting?
- Anteris Technologies Global Corp (AVR) holds its 2025 special shareholder meeting on Thursday, September 4, 2025.
- What is the record date for the Anteris Technologies Global Corp 2025 meeting?
- The record date for the Anteris Technologies Global Corp 2025 meeting is Monday, August 11, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Anteris Technologies Global Corp's 2025 meeting?
- The board is presenting 7 director nominees at the Anteris Technologies Global Corp 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Anteris Technologies Global Corp 2025 meeting?
- Shareholders will vote on 2 proposals at the Anteris Technologies Global Corp 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.